CCB International: Maintaining Rongchang Biotech's (09995.HK) “Outperform the Market” rating and raising the target price to HK$34
Guoxin Securities released a research report on April 8 stating that it gave Rongchang Biotech (688331.SH) an increase in its holdings. The main reasons for the rating include: 1) commercialization of core products is progressing well; 2) clinical promoti
Rongchang Biotech (9995.HK): Strong revenue growth, clinical progress continues to be steady
Rongchang Biotech (688331): Sales of core products continue to grow, clinical development progresses in an orderly manner
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ramsay Health Care (OtherRMSYF), Glass House Brands (OtherGLASF) and RemeGen Co. Ltd. Class H (HK:9995)
Rongchang Biotech (688331): Strong commercialization of main products, growing innovative drug echelons
REMEGEN(9995.HK):AWAITING THE FRUITION OF OVERSEAS BD COLLABORATIONS
REMEGEN CO LTD(9995.HK):SOFT COMMERCIALISATION IN 2023;GUIDANCE OF AT LEAST 50% YOY GROWTH IN DRUG SALES IN 2024
REMEGEN(09995.HK):SALES RAMP UP WITH R&D ACHIEVEMENTS
Rongchang Biotech (688331): Core product volume+offshore +fixed growth BIOTECH leader has set sail again
Rongchang Biotech (688331): Sales of core products increased significantly, and the pace of overseas clinical progress accelerated
Rongchang Biology (688331): Core products, multiple clinical trials at home and abroad are carried out in an orderly manner, and follow-up pipelines continue to advance
Rongchang Biotech (9995.HK): Performance is in line with expectations, commercialization is expected to accelerate implementation
Rongchang Biotech (688331): Continued release of core products, looking forward to overseas progress
Rongchang Biotech (9995.HK): Strong revenue from FY23 products, FY24 focuses on Taixip's overseas progress and maintains a buying rating
Rongchang Biotech (688331): ADC+ free dual drive looks forward to a breakthrough in internationalization
Rongchang Biotech (688331): Innovative products successfully released Taytacip and made significant progress in overseas clinical trials
CCB International: Maintaining Rongchang Biotech's (09995) “Outperform the Market” rating and reducing the target price by 47% to HK$26
Rongchang Biotech (9995.HK): Revenue is basically in line with expectations, and the company's pipeline continues to advance
Rongchang Biotech (688331): Stable revenue growth pipeline is progressing smoothly
No Data